UpThera by UpTake Theranostics: the operating platform for modern theranostics
Concept image.
Software + Expert Support
More Than Software. A Partner in Theranostics.
From launching your theranostics program to supporting daily operations, UpThera brings together the technology, training, documentation, and expert support your team needs.
Establish your program. Train your team. Stay ready.
- Turnkey US Licensing & Risk Analysis
- SOPs & Authorized User Training
- Extravasation Dosimetry & Incident Support
- On-Demand Staffing Support
Education Center
Train Your Team in a Virtual Hot Lab
Explore role-based radiation safety lessons, interactive hot-lab simulations, and knowledge checks for nurses, technologists, and support staff.
Explore Education CenterPreview the pilot curriculum. No account required.
Documentation + Implementation
PLUVICTO® Documentation & Implementation Support
Editable SOPs, treatment checklists, administration records, patient instructions, and a treatment ID card. We help adapt the documentation to your facility and support your team with training and workflow setup.
- SOPs & supporting forms
- Facility customization
- Training & workflow setup
PLUVICTO only. Documents require facility customization and clinical approval before use.
Scope and pricing based on your needs.
Planning for Ac-225? Ask about preparation and staff training. Clinical implementation is subject to product-specific approvals, applicable licensing, and facility authorization.
Everything your program needs, connected.
One integrated platform and expert support for safe, well-documented care.
- Therapy OperationsScheduling, rooms, deliveries and Therapy Closeout.
- Radiation Safety & DoseSurveys, events, waste, instruments and the Dose & Activity Registry.
- People & LicensingTraining, SOPs, credentials and Authorized User onboarding.
- RSC ReportingCommittee reports traced back to the source records.
The Science ofAlpha Therapy. Still Being Written.
Ac-225 is a promising alpha emitter with the potential to deliver potent, targeted radiation to cancer cells. Research is ongoing to better understand its full potential, including safety, dosing, and practical use.
Illustration, not to scaleSee how Ac-225 steps down through its daughters
An interactive animation of the Ac-225 decay chain. Select any nucleus to see what it emits and how long it lasts.
- Interactive
- Works on phones
Why daughter emissions matter for shielding
Ac-225 decays through a series of short-lived daughter isotopes that emit additional radiation, including alpha, beta, and gamma. These emissions can affect radiation safety, handling, and shielding considerations in clinical and research settings.
How Pb-212 compares
Pb-212’s decay chain includes a high-energy photon from Tl-208, making shielding considerations different from those for Tc-99m or Lu-177.
Explore the physicsWhat changes for staff handling alpha emittersA short look at hands, spills and distance, from a 2025 radiation protection paper
Alpha particles travel less than 100 µm, so once the drug is in the patient the exposure outside is very small. The risks sit in handling the dose, in a spill, and in how the injection is done.
Published estimates for 8 MBq of Ac-225, in a worst-case scenario.
Distance does most of the work
Estimated dose to the hand during an injection, for the same 120 seconds.
2.9 mSv
Holding it 5 cm away gives a hand dose about 1,100 times lower. This is why holders, tongs and a steady technique are part of the procedure.
Preparing a dose
About 120 s handling the vial and 300 s standing 30 cm away, with the vial in a lead holder.
- Hand, at contact
- 48 µSv
- Whole body, at 30 cm
- 0.28 µSv
Giving the injection
About 120 s with the syringe, 300 s at 30 cm. Beta-gamma shielding is recommended in this phase.
- Hand, at contact
- 2.9 mSv
- Whole body, at 30 cm
- 0.29 µSv
Caring for the patient
About 10 minutes at 50 cm after the injection, with no shielding.
- Whole body, at 50 cm
- 0.21 µSv
If there is a spill
The skin matters more than the whole body. If the whole vial contents reached the skin, the paper estimates about 140 mSv spread evenly or about 67 mSv from a single drop, while the whole-body dose from decontaminating the floor is under 1 µSv.
The paper calls this deliberately conservative; it expects a realistic dose to be an order of magnitude or more lower. Gloves and a prompt response are what keep it there.
Shielding in practice
- Lead holders for the photon emissions and plexiglass for the beta. The IAEA recommends shielding alpha emitters because of their X-ray and gamma emissions.
- Double gloves, tools that add distance, and single-use equipment.
- An absorbent pad around the injection site in case of a spill.
Read this as an illustration. These are published worst-case estimates, not measurements, built mostly on Ra-223 experience in a European setting. They are not a facility assessment, a shielding design, or a decision about whether anyone may be released. Your radiation safety officer and licence conditions decide those.
Source: Sarnelli A, Mezzenga E, Kollaard R, Winters EG, De With G, Mikołajczak R. Targeted alpha therapy in the clinical practice: radiation protection considerations. Eur Phys J Plus 140, 804 (2025). doi.org/10.1140/epjp/s13360-025-06709-y. CC BY 4.0. Values for 8 MBq of Ac-225 from the paper's Tables 4, 6, 10 and 11, shown in simplified form.
New · Free registration
UpThera Staffing & Specialist Network
Connecting healthcare facilities with experienced nuclear medicine technologists and theranostic professionals.
Free network registration. Staffing services subject to availability, qualification verification, and applicable service agreements.
- Nuclear medicine technologistsPRN shifts and short-term cover, including PET/CT and therapy days.
- Medical physicistsProgram launches, surveys, shielding and radiation safety support.
- Theranostics specialistsRSOs, nurses and program specialists for Lu-177, Y-90, I-131 and Ra-223.
Building or growing a Theranostics program?
Partner with UpThera for the software and expertise you need to run it safely and well.